Solid Biosciences Inc.
Символ: SLDB
NASDAQ
9.26
USDПазарна цена днес
-1.8857
Съотношение P/E
0.0483
Коефициент PEG
349.63M
MRK Cap
- 0.00%
Доходност на DIV
Solid Biosciences Inc. (SLDB) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 612.23 | 123.6 | 213.7 | 207.8 | |||||||||
balance-sheet.row.short-term-investments | 232.96 | 49.6 | 58.3 | 88.6 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 6 | |||||||||
balance-sheet.row.other-current-assets | 14.25 | 6.1 | 5.9 | 8.7 | |||||||||
balance-sheet.row.total-current-assets | 636.16 | 129.7 | 219.6 | 222.6 | |||||||||
balance-sheet.row.property-plant-equipment-net | 139.54 | 33.2 | 38.6 | 7.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 7.33 | 1.8 | 1.8 | 2.1 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0.94 | 0.2 | 0.2 | 0.1 | |||||||||
balance-sheet.row.total-non-current-assets | 147.82 | 35.2 | 40.6 | 9.8 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.account-payables | 12.49 | 2 | 3.2 | 4.5 | |||||||||
balance-sheet.row.short-term-debt | 9.14 | 2.3 | 2.6 | 1.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 99.13 | 23.9 | 26 | 0.6 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 22.88 | 10.2 | 16.7 | 9.6 | |||||||||
balance-sheet.row.total-non-current-liabilities | 99.13 | 23.9 | 26.1 | 0.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 105.95 | 23.9 | 28.5 | 2.1 | |||||||||
balance-sheet.row.total-liab | 165.62 | 38.5 | 48.6 | 24.2 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0.08 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.retained-earnings | -2507.41 | -658.8 | -562.7 | -476.8 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.04 | 0 | -0.1 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 3125.66 | 785.2 | 774.5 | 684.9 | |||||||||
balance-sheet.row.total-stockholders-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.98 | - | - | - | |||||||||
Total Investments | 234.79 | 51.5 | 58.3 | 88.6 | |||||||||
balance-sheet.row.total-debt | 108.27 | 26.3 | 28.5 | 2.1 | |||||||||
balance-sheet.row.net-debt | -271 | -47.8 | -126.8 | -117.1 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -96.02 | -96 | -86 | -72.2 | |||||||||
cash-flows.row.depreciation-and-amortization | 2.96 | 2.6 | 2.4 | 3 | |||||||||
cash-flows.row.deferred-income-tax | -46.06 | -13.6 | 0 | 1.2 | |||||||||
cash-flows.row.stock-based-compensation | 7.63 | 7.6 | 7.5 | 13.4 | |||||||||
cash-flows.row.change-in-working-capital | -6.34 | -6.3 | -3.7 | -23 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.1 | -0.1 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | -11.5 | |||||||||
cash-flows.row.account-payables | -0.76 | -0.8 | -5.2 | 1.2 | |||||||||
cash-flows.row.other-working-capital | -4.67 | -5.6 | 1.4 | -12.6 | |||||||||
cash-flows.row.other-non-cash-items | 43.65 | 11.5 | -18.3 | -0.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -94.18 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.acquisitions-net | 71.95 | -9.7 | 31.5 | 89.8 | |||||||||
cash-flows.row.purchases-of-investments | -117.43 | -117.4 | -182.8 | -141.2 | |||||||||
cash-flows.row.sales-maturities-of-investments | 128.63 | 128.6 | 212.8 | 51.4 | |||||||||
cash-flows.row.other-investing-activites | -71.95 | 9.7 | 0.6 | -89.8 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 9.69 | 9.7 | 59.2 | -91.1 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||||
cash-flows.row.common-stock-issued | 5.51 | 3 | 72.6 | 134.9 | |||||||||
cash-flows.row.common-stock-repurchased | 0.16 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | -5.16 | 0.1 | 2.3 | 0.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.74 | 3.1 | 74.8 | 135 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 76.19 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -81.37 | -81.4 | 36 | -33.9 | |||||||||
cash-flows.row.cash-at-end-of-period | 384.77 | 74 | 157.2 | 121.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 466.14 | 155.4 | 121.2 | 155.1 | |||||||||
cash-flows.row.operating-cash-flow | -94.18 | -94.2 | -98 | -77.8 | |||||||||
cash-flows.row.capital-expenditure | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.free-cash-flow | -95.69 | -95.7 | -101 | -79 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 8.1 | 13.6 | |||||||||
income-statement-row.row.cost-of-revenue | 2.96 | 2.6 | 2.4 | 0 | |||||||||
income-statement-row.row.gross-profit | -2.96 | -2.6 | 5.7 | 13.6 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 76.56 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 27.75 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.operating-expenses | 103.73 | 101.7 | 107.4 | 85.9 | |||||||||
income-statement-row.row.cost-and-expenses | 104.31 | 104.3 | 107.4 | 85.9 | |||||||||
income-statement-row.row.interest-income | 7.14 | 7.1 | 2.6 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 2.96 | 2.6 | -1.5 | 3 | |||||||||
income-statement-row.row.ebitda-caps | -102.01 | - | - | - | |||||||||
income-statement-row.row.operating-income | -104.25 | -104.3 | -106.5 | -72.3 | |||||||||
income-statement-row.row.income-before-tax | -96.02 | -96 | -86 | -72.2 | |||||||||
income-statement-row.row.income-tax-expense | -4.56 | 0 | -20.5 | -0.1 | |||||||||
income-statement-row.row.net-income | -94.06 | -96 | -65.5 | -72.1 |
Често задавани въпроси
Какво е Solid Biosciences Inc. (SLDB) общи активи?
Solid Biosciences Inc. (SLDB) общите активи са 164939000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са N/A.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -4.694.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -4.694.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.000.
Какъв е общият приход на предприятието?
Общият приход е 0.000.
Каква е Solid Biosciences Inc. (SLDB) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -96015000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 26265000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 101734000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 74015000.000.